Posted On: 06/04/2013 6:14:22 PM
Post# of 72446
Thanks Kelt.........hey I really like this post by JB. His view makes more sense IMO than all of the howling at the Moon about P21 I read elsewhere.....wonder what you think of it
Cellceutix Corporation (CTIX)
Dr. Menon continued, "Some very exciting times are
Public Reply | Private Reply | Keep | Last Read Post New Msg Previous | Next
JB3729
Tuesday, June 04, 2013 5:35:14 PM
Re: None
Post # of 33949
Dr. Menon continued, "Some very exciting times are approaching as we expect to reach Maximum Tolerated Dose between the sixth and ninth cohorts. We also look forward to data on the p21 biomarker, which was not available for the ASCO meeting as the laboratory moves the samples into queue, in the coming weeks.
queue definition = A queue is a list of jobs that are awaiting to be processed. When a job is sent to a queue, it is simply added to the list of jobs.
At the Ideas Conference on May 15th, Dr. Holden stated that the hospital had just sent more samples to the lab. She also stated that Dana Farber has about 600 trials running. Obviously, the laboratory didn't drop everything else and process Cellceutix's trial samples.
From the pre-ASCO PR - The laboratory informed us that additional samples were required for analysis of Kevetrin’s affect on biomarker p21, an early-stage indicator of efficacy. Those samples have been supplied by the hospital with more to be delivered as the trial progresses. We are hopeful that data will be available in time for ASCO.”
So, the lab wasn't able to complete their analysis of the samples in 3 weeks. I do think CTIX will PR the p21 data when the lab has completed their work. Maybe results come as early as Friday!
Cellceutix Corporation (CTIX)
Dr. Menon continued, "Some very exciting times are
Public Reply | Private Reply | Keep | Last Read Post New Msg Previous | Next
JB3729
Tuesday, June 04, 2013 5:35:14 PM
Re: None
Post # of 33949
Dr. Menon continued, "Some very exciting times are approaching as we expect to reach Maximum Tolerated Dose between the sixth and ninth cohorts. We also look forward to data on the p21 biomarker, which was not available for the ASCO meeting as the laboratory moves the samples into queue, in the coming weeks.
queue definition = A queue is a list of jobs that are awaiting to be processed. When a job is sent to a queue, it is simply added to the list of jobs.
At the Ideas Conference on May 15th, Dr. Holden stated that the hospital had just sent more samples to the lab. She also stated that Dana Farber has about 600 trials running. Obviously, the laboratory didn't drop everything else and process Cellceutix's trial samples.
From the pre-ASCO PR - The laboratory informed us that additional samples were required for analysis of Kevetrin’s affect on biomarker p21, an early-stage indicator of efficacy. Those samples have been supplied by the hospital with more to be delivered as the trial progresses. We are hopeful that data will be available in time for ASCO.”
So, the lab wasn't able to complete their analysis of the samples in 3 weeks. I do think CTIX will PR the p21 data when the lab has completed their work. Maybe results come as early as Friday!
(0)
(0)
